Rahmani, M., Aust, M. M., Hawkins, E., Parker, R. E., Ross, M., Kmieciak, M., . . . Grant, S. (2015). Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. Haematologica.
Citação norma ChicagoRahmani, Mohamed, et al. "Co-administration of the MTORC1/TORC2 Inhibitor INK128 and the Bcl-2/Bcl-xL Antagonist ABT-737 Kills Human Myeloid Leukemia Cells Through Mcl-1 Down-regulation and AKT Inactivation." Haematologica 2015.
Citação norma MLARahmani, Mohamed, et al. "Co-administration of the MTORC1/TORC2 Inhibitor INK128 and the Bcl-2/Bcl-xL Antagonist ABT-737 Kills Human Myeloid Leukemia Cells Through Mcl-1 Down-regulation and AKT Inactivation." Haematologica 2015.